⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 11, 2024International ImmunopharmacologyOpen Access

Distinct disease-modifying therapies are associated with different blood immune cell profiles in people with relapsing-remitting multiple sclerosis

João Canto-Gomes Daniela Boleixa Catarina Teixeira Ana Silva Inés González‐Suarez João Cerqueira Margarida Correia‐Neves Cláudia Nóbrega

View Full Paper

Ask AI

Bookmark

Share

Abstract

Disease modifying therapies (DMTs) used for treating people with relapsing-remitting multiple sclerosis (pwRRMS) target the immune system by different mechanisms of action. However, there is a lack of a comprehensive assessment of their effects on the immune system in comparison to treatment-naïve pwRRMS. Herein, we evaluated the numbers of circulating B cells, CD4

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Canto-Gomes et al. (2024) studied this question.

synapsesocial.com/papers/68e7493fb6db6435876c1e24 https://doi.org/10.1016/j.intimp.2024.111826

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Disease modifying therapies for relapsing multiple sclerosisRCT · 2016 · 165 citations
2Comparative Analysis of Disease-Modifying Therapies for Multiple Sclerosis2025
3Update on Disease-Modifying Therapies for Multiple Sclerosisreview · 2017 · 138 citations
4Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination2024 · 4 citations
5Adjunctive Non-Disease-Modifying Therapies in Multiple Sclerosis: Immunometabolic, Neuroprotective and Remyelination-Oriented ApproachesClinical Trial · 2026